Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Basic): 2018-2024

Historic EPS (Basic) for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to -$0.33.

  • Silence Therapeutics' EPS (Basic) rose 40.00% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.15, marking a year-over-year increase of 40.00%. This contributed to the annual value of -$0.33 for FY2024, which is 32.65% up from last year.
  • Per Silence Therapeutics' latest filing, its EPS (Basic) stood at -$0.33 for FY2024, which was up 32.65% from -$0.49 recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' EPS (Basic) registered a high of -$0.33 during FY2024, and its lowest value of -$0.52 during FY2022.
  • In the last 3 years, Silence Therapeutics' EPS (Basic) had a median value of -$0.49 in 2023 and averaged -$0.45.
  • In the last 5 years, Silence Therapeutics' EPS (Basic) tumbled by 53.36% in 2020 and then skyrocketed by 32.65% in 2024.
  • Over the past 4 years, Silence Therapeutics' EPS (Basic) (MRY) stood at -$0.51 in 2020, then dropped by 1.74% to -$0.52 in 2022, then grew by 5.77% to -$0.49 in 2023, then skyrocketed by 32.65% to -$0.33 in 2024.
  • Its EPS (Basic) was -$0.33 in FY2024, compared to -$0.49 in FY2023 and -$0.52 in FY2022.